Pharma Strategy Blog

ASCO 2012 Preview – Highlights of key data emerging from Chicago

MaverickNY — Tue, 15 May 2012 18:06:17 +0000

It’s that time of the year again where we cogitate and contemplate on what might be hot at the annual meeting of the American Society of Clinical Oncology (ASCO) before the abstracts are available (they’re released online tomorrow at 6pm … Continue reading →

ASCO 2012 Acronym Mania!

MaverickNY — Mon, 14 May 2012 16:08:29 +0000

Many of you will remember PSB reader Dr Al Lalani of Regeneron’s guest blog post around this time last year with a quick summary of the key clinical trials at the American Society of Clinical Oncology (ASCO) meeting based on … Continue reading →

Ribonucleases (RNase) – clinical applications for cancer therapy

MaverickNY — Tue, 01 May 2012 12:14:29 +0000

This is the second post of a two-part mini series on RNases with Dr Laura Strong of Quintessence Biosciences. If you haven’t yet read it, check out yesterday’s post, which focused on Ribonucleases (RNase) – what are they and why … Continue reading →

Ribonucleases (RNase) what are they and why are they relevant to cancer?

MaverickNY — Mon, 30 Apr 2012 14:12:56 +0000

At the recent American Association for Cancer Research (AACR) meeting, I had the pleasure of meeting several interesting young scientists and physicians either in the poster halls or in various scientific sessions. It seemed a great idea to encourage some … Continue reading →

Highlights of AACR 2012 – Part 3

MaverickNY — Mon, 23 Apr 2012 16:00:38 +0000

Aside from the already published Part 1 and Part 2 blog posts about AACR here on PSB, you can also find some more coverage, including summaries of other topics, on the companion Biotech Strategy Blog, such as the following: SARDs, … Continue reading →

Highlights of AACR 2012 – Part 2

MaverickNY — Wed, 18 Apr 2012 16:25:37 +0000

Yesterday, I mentioned that some of the best bits of this year’s American Association for Cancer Research (AACR) meeting were the numerous gems in the poster sessions. One of the coolest such posters I came across was from Ming Tsao’s … Continue reading →

Highlights of AACR 2012 – Part 1

MaverickNY — Tue, 17 Apr 2012 12:31:19 +0000

The 2012 American Association for Cancer Research (AACR) meeting in Chicago was interesting for several reasons. While there were no truly ground breaking data such as in previous years as with, for example: vemurafenib in BRAFV600E melanoma vismodegib in basal cell … Continue reading →

American Association for Cancer Research Meeting 2012

MaverickNY — Sat, 31 Mar 2012 12:03:02 +0000

Today marks the kick off for one of my favourite conferences on the oncology-hematology calendar, with the annual meeting of the American Association for Cancer Research (AACR) being held in Chicago. It’s all about the science and basic research here, … Continue reading →

On adaptive mechanisms of crizotinib resistance in ALK-positive lung cancer

MaverickNY — Fri, 23 Mar 2012 16:51:52 +0000

One of the biggest challenges facing cancer research was aptly summarised by Levi Garraway and Pasi Jänne in this month’s Cancer Discovery journal: “All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding … Continue reading →

J&J unblind Zytiga phase 3 trial in pre-chemotherapy castrate-resistant prostate cancer

MaverickNY — Thu, 08 Mar 2012 18:01:03 +0000

The big cancer news that hit the news wires this morning was not entirely surprising: “Janssen Research & Development, LLC today announced that it has unblinded the Phase 3 study of ZYTIGA (abiraterone acetate) plus prednisone for the treatment of … Continue reading →